id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-331283-bfyoavon	Meca-Lallana, Dra. Virginia	COVID-19 IN 7 MULTIPLE SCLEROSIS PATIENTS IN TREATMENT WITH ANTI-CD20 THERAPIES	2020-06-15		.txt	text/plain	1223	85	53	We describe our experience in seven cases of patients with multiple sclerosis who have been affected by SARS-COV-2 (with a clinical/serological diagnosis or PCR diagnosis) and who were being treated with anti-CD20+ monoclonal antibodies. CONCLUSIONS: Patients treated with anti-CD20+ have adequate resolution of COVID-19 despite the fact that the presence of antibodies against SARS-CoV-2 was not detected in all cases. Ocrelizumab is associated with decreased levels of IgM (and to a lesser degree for IgA and IgG), and serious infections occurred, but their incidence was low in clinical trials and extended phases 4 In this work, we report our experience in MS patients with anti-CD20+ antibodies who have 2. We have found antibodies against SARS-CoV-2 in patients treated with ocrelizumab, but in patients who previously used rituximab this immunity is not achieved or we are not able to detect it.	./cache/cord-331283-bfyoavon.txt	./txt/cord-331283-bfyoavon.txt